NASDAQ:PTLA', 'Portola Pharmaceuticals Inc.', '');

Cormorant Asset Management LLC Has Raised Portola Pharmaceuticals INC (PTLA) Position by $16.80 Million

December 9, 2017 - By Clifton Ray

Investors sentiment decreased to 1.31 in 2017 Q2. Its down 0.29, from 1.6 in 2017Q1. It dropped, as 17 investors sold PTLA shares while 58 reduced holdings. 45 funds opened positions while 53 raised stakes. 48.64 million shares or 0.79% more from 48.26 million shares in 2017Q1 were reported. Castleark Mgmt Ltd Liability Com invested 0.08% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Manufacturers Life Ins The holds 38,612 shares or 0% of its portfolio. Metropolitan Life Insur New York invested in 0.01% or 34,415 shares. Guggenheim Capital Limited Liability Co holds 86,149 shares or 0.01% of its portfolio. Chicago Equity Prtn Ltd Llc invested in 0.01% or 5,645 shares. State Bank Of Montreal Can reported 535 shares. Us Bancshares De owns 41,154 shares. Qs Invsts Ltd Liability Corporation holds 2,611 shares. Quantitative Inv Mgmt Limited Liability reported 0.05% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Rothschild Investment Corporation Il owns 20,880 shares. Massachusetts-based Numeric Ltd Liability Corp has invested 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). California State Teachers Retirement System reported 88,055 shares. 2.09 million were reported by State Street Corp. Schwab Charles Investment Mgmt holds 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 228,187 shares. Credit Suisse Ag has 0.01% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Cormorant Asset Management Llc increased its stake in Portola Pharmaceuticals Inc (PTLA) by 50% based on its latest 2017Q2 regulatory filing with the SEC. Cormorant Asset Management Llc bought 300,000 shares as the company’s stock rose 22.73% with the market. The hedge fund held 900,000 shares of the health care company at the end of 2017Q2, valued at $50.55 million, up from 600,000 at the end of the previous reported quarter. Cormorant Asset Management Llc who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $3.46B market cap company. The stock increased 0.59% or $0.31 during the last trading session, reaching $53.02. About 713,244 shares traded. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since December 9, 2016 and is uptrending. It has outperformed by 34.47% the S&P500.

More recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: which released: “Partner Fund Management, LP Buys Portola Pharmaceuticals Inc, Centene Corp …” on November 16, 2017. Also published the news titled: “Portola Pharmaceuticals Provides Update on Bevyxxa® (betrixaban) Commercial Launch” on November 21, 2017.‘s news article titled: “Portola Pharmaceuticals Inc (NASDAQ:PTLA) Bullish Divergence” with publication date: November 22, 2017 was also an interesting one.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 6 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Portola Pharmaceuticals had 29 analyst reports since August 5, 2015 according to SRatingsIntel. Goldman Sachs initiated it with “Buy” rating and $75.0 target in Friday, December 1 report. Credit Suisse maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) on Thursday, August 10 with “Hold” rating. On Monday, August 28 the stock rating was maintained by Oppenheimer with “Buy”. Oppenheimer maintained the stock with “Buy” rating in Monday, June 26 report. The firm has “Neutral” rating by Citigroup given on Friday, August 19. Morgan Stanley maintained it with “Overweight” rating and $81 target in Friday, October 6 report. The rating was maintained by Cowen & Co on Monday, June 26 with “Buy”. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) earned “Buy” rating by Cowen & Co on Wednesday, August 9. Oppenheimer maintained the shares of PTLA in report on Friday, August 4 with “Buy” rating. Credit Suisse downgraded Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Tuesday, May 31. Credit Suisse has “Neutral” rating and $30 target.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.